Detailed Information

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Cited 12 time in Web of Science Cited 11 time in Scopus

Lee, Han Ah; Chang, Young; Sung, Pil Soo; Yoon, Eileen L.; Lee, Hye Won; Yoo, Jeong-Ju; Lee, Young-Sun; An, Jihyun; Song, Do Seon; Cho, Young Youn; Kim, Seung Up; Kim, Yoon Jun

Issue Date
Clinical and Molecular Hepatology, Vol.28 No.3, pp.425-472
The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment in nonalcoholic fatty liver disease, the beneficial effects of antidiabetics and non???antidiabetics in clinical practice have been continuously investigated in patients with CLD. In this narrative review, we focused on non-antidiabetic drugs, including ursodeoxycholic acid, silymarin, dimethyl-4,4???-dimethoxy-5,6,5???,6???-dimethylenedixoybiphenyl-2,2???-dicarboxylate, L-ornithine L-aspartate, branched chain amino acids, statin, probiotics, vitamin E, and aspirin, and summarized their beneficial effects in CLD. Based on the antioxidant, anti-inflammatory properties, and regulatory functions in glucose or lipid metabolism, several non???antidiabetic drugs have shown beneficial effects in improving liver histology, aminotransferase level, and metabolic parameters and reducing risks of hepatocellular carcinoma and mortality, without significant safety concerns, in patients with CLD. Although the effect as the centerpiece management in patients with CLD is not robust, the use of these non-antidiabetic drugs might be potentially beneficial as an adjuvant or combined treatment strategy. (Clin Mol Hepatol 2022;28:425-472)
Files in This Item:
There are no files associated with this item.
Appears in Collections:


Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.